These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 3508655)
1. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines. Ozaki K; Kuno-Sakai H; Kimura M Tokai J Exp Clin Med; 1987 Dec; 12(5-6):305-11. PubMed ID: 3508655 [TBL] [Abstract][Full Text] [Related]
2. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276 [TBL] [Abstract][Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Just M; Berger R; Just V Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Glikmann G; Petersen I; Mordhorst CH Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817 [TBL] [Abstract][Full Text] [Related]
6. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. André FE; Peetermans J Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770 [TBL] [Abstract][Full Text] [Related]
7. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps]. Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598 [TBL] [Abstract][Full Text] [Related]
8. The combination measles, mumps, rubella and varicella vaccine in healthy children. Arbeter AM; Baker L; Starr SE; Plotkin SA Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Just M; Berger R; Glück R; Wegmann A Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399 [TBL] [Abstract][Full Text] [Related]
10. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673 [TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus. Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112 [TBL] [Abstract][Full Text] [Related]
12. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
13. Combined vaccine against measles, mumps, rubella, and varicella. Brunell PA; Novelli VM; Lipton SV; Pollock B Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743 [TBL] [Abstract][Full Text] [Related]
14. Effects and side effects of a new trivalent combined measles-mumps-rubella (MMR) vaccine. Isozaki M; Kuno-Sakai H; Hoshi N; Takesue R; Takakura I; Kimura M; Hikino M; Mitsuda M Tokai J Exp Clin Med; 1982 Sep; 7(5):547-50. PubMed ID: 7182947 [TBL] [Abstract][Full Text] [Related]
15. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Dennehy PH; Saracen CL; Peter G Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862 [TBL] [Abstract][Full Text] [Related]
16. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946 [TBL] [Abstract][Full Text] [Related]
17. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661 [TBL] [Abstract][Full Text] [Related]
18. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related]
19. [Mumps epidemic in vaccinated children in West Switzerland]. Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835 [TBL] [Abstract][Full Text] [Related]
20. Comparative study and evaluation of further attenuated, live measles vaccines alone and in combination with mumps and rubella vaccines. Wegmann A; Glück R; Just M; Mischler R; Paroz P; Germanier R Dev Biol Stand; 1986; 65():69-74. PubMed ID: 3556778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]